Taken in conjunction with the findings presented here, this suggests a need for future studies to determine whether a combination therapy approach represents a potential means for a more pronounced reduction of MDSC‐derived MPO within the MM tumour microenvironment accompanied by a direct effect on MM PC survival, and thus a more complete response to treatment. This evidence concerns the gene MPO and Miyoshi myopathy.